Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (21-30 of 372) with videos related to

Pageof 38
Sort By:
Presse Medicale (Paris, France : 1983)|August 25, 2019
[Waldenström macroglobulinaemia]Cécile Tomowiak, Stéphanie Poulain, Céline Debiais, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|June 3, 2008
Targeted therapies in Waldenström macroglobulinemiaNicholas Burwick, Aldo M Roccaro, Xavier Leleu, et al.
Haematologica|April 2, 2014
Understanding the multiple biological aspects leading to myelomaEileen M Boyle, Faith E Davies, Xavier Leleu, et al.
Expert Review of Hematology|December 7, 2013
Initial treatment of transplant-ineligible patients in multiple myelomaMaría-Victoria Mateos, Xavier Leleu, Antonio Palumbo, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2024
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple MyelomaHang Quach, Gurdeep Parmar, Maria-Victoria Mateos, et al.
Haematologica|November 10, 2004
Evaluation of gemcitabine in relapsed or refractory multiple myelomaXavier Leleu, Jacques Troncy, Fadela Bouafia, et al.
Haematologica|May 30, 2008
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or lessStéphanie Poulain, Isabelle Dervite, Xavier Leleu, et al.
Open Journal of Hematology|July 31, 2012
Novel agents in Waldenstrom MacroglobulinemiaAntonio Sacco, Xavier Leleu, Giuseppe Rossi, et al.
Cancer|October 23, 2020
Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective studyEmilie Cayssials, Jose Torregrosa-Diaz, Xavier Leleu, et al.
American Journal of Hematology|October 17, 2019
Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE scoreEmilie Chalayer, Alice Teste, Denis Guyotat, et al.
Pageof 38

Showing results (21-30 of 372) with videos related to

Sort By:
Pageof 38
Presse Medicale (Paris, France : 1983)|August 25, 2019
[Waldenström macroglobulinaemia]Cécile Tomowiak, Stéphanie Poulain, Céline Debiais, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|June 3, 2008
Targeted therapies in Waldenström macroglobulinemiaNicholas Burwick, Aldo M Roccaro, Xavier Leleu, et al.
Haematologica|April 2, 2014
Understanding the multiple biological aspects leading to myelomaEileen M Boyle, Faith E Davies, Xavier Leleu, et al.
Expert Review of Hematology|December 7, 2013
Initial treatment of transplant-ineligible patients in multiple myelomaMaría-Victoria Mateos, Xavier Leleu, Antonio Palumbo, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2024
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple MyelomaHang Quach, Gurdeep Parmar, Maria-Victoria Mateos, et al.
Haematologica|November 10, 2004
Evaluation of gemcitabine in relapsed or refractory multiple myelomaXavier Leleu, Jacques Troncy, Fadela Bouafia, et al.
Haematologica|May 30, 2008
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or lessStéphanie Poulain, Isabelle Dervite, Xavier Leleu, et al.
Open Journal of Hematology|July 31, 2012
Novel agents in Waldenstrom MacroglobulinemiaAntonio Sacco, Xavier Leleu, Giuseppe Rossi, et al.
Cancer|October 23, 2020
Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective studyEmilie Cayssials, Jose Torregrosa-Diaz, Xavier Leleu, et al.
American Journal of Hematology|October 17, 2019
Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE scoreEmilie Chalayer, Alice Teste, Denis Guyotat, et al.
Pageof 38